DK1812031T3 - Sammensætninger og fremgangsmåder til modificering af biomolekyler - Google Patents

Sammensætninger og fremgangsmåder til modificering af biomolekyler Download PDF

Info

Publication number
DK1812031T3
DK1812031T3 DK05823231.5T DK05823231T DK1812031T3 DK 1812031 T3 DK1812031 T3 DK 1812031T3 DK 05823231 T DK05823231 T DK 05823231T DK 1812031 T3 DK1812031 T3 DK 1812031T3
Authority
DK
Denmark
Prior art keywords
ester
compound
nitro
sulfonyl
azide
Prior art date
Application number
DK05823231.5T
Other languages
English (en)
Inventor
Carolyn R Bertozzi
Jeremy Michael Baskin
Nicholas J Agard
Jennifer A Prescher
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK1812031T3 publication Critical patent/DK1812031T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/457—Saturated compounds containing a keto group being part of a ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/68—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings containing halogen
    • C07C63/74—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings containing halogen having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (27)

1. Forbindelse med formlen:
hvor: hvert af X og X' uafhængigt er: (a) et eller to halogenatomer (e.g., bromo, chlor, fluor, iodo); (b) -W-(CH2)n-Z, hvor n er et helt tal fra 1-4; hvor W, hvis til stede, er O, N eller S; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; (c) -(CH2)n-W-(CH2)m-Z, hvor n og m hver især uafhængigt er 1 eller 2; hvor W er O, N, S eller sulfonyl; forudsat at hvis W er O, N eller S, så er Z nitro, cyano eller halogen; og forudsat at hvis W er sulfonyl, så er Z H; eller (d) -(CH2)n-Z, hvor n er et helt tal fra 1 -4; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; Y er H; en reaktiv gruppe udvalgt fra et carboxyl, en amin, en ester, en thioester, et sulfonylhalid, en alkohol, en thiol, en succinimidylester, et isothiocyanat, et iodoacetamid, et maleimid og et hydrazin; eller en detekter-bar markering, et lægemiddel, et toksin, et peptid, et polypeptid, en epitop-tag eller et medlem af et specifikt bindingspar; og Ri er udvalgt fra en carboxylsyre, en alkylester, en arylester, en substitueret arylester, et aldehyd, et amid, et arylamid, et alkylhalid, en thioester, en sul-fonylester, en alkylketon, en arylketon, en substitueret arylketon, et halosul-fonyl, en nitril og et nitro; eller hvert af X og X' uafhængigt er: (a) H; (b) et eller to halogenatomer (f.eks. bromo, chlor, fluor, iodo); (c) -W-(CH2)n-Z, hvor n er et helt tal fra 1-4; hvor W, hvis til stede, er O, N eller S; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; (d) -(CH2)n-W-(CH2)m-Z, hvor n og m hver især uafhængigt er 1 eller 2; hvor W er O, N, S eller sulfonyl; forudsat at hvis W er O, N eller S, så er Z nitro, cyano eller halogen; og forudsat at hvis W er sulfonyl, så er Z H; eller (e) -(CH2)n-Z, hvor n er et helt tal fra 1 -4; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; Y er et carboxyl, et amin, en thioester, et sulfonylhalid, en alkohol, en thiol, en succinimidylester, et isothiocyanat, et iodoacetamid, et maleimid eller et hydrazin; eller en fluorescerende markering, et lægemiddel, et toksin, et peptid, et polypeptid, et epitop-tag eller et medlem af et specifikt bindingspar; og Ri er udvalgt fra en carboxylsyre, en alkylester, en arylester, en substitueret arylester, et aldehyd, et amid, et arylamid, et alkylhalid, en thioester, en sul-fonylester, en alkylketon, en arylketon, en substitueret arylketon, et halosul-fonyl, en nitril og et nitro.
2. Forbindelse ifølge krav 1, hvor: hvert af X og X' uafhængigt er: (a) et eller to halogenatomer (e.g., bromo, chlor, fluor, iodo); (b) -W-(CH2)n-Z, hvor n er et helt tal fra 1-4; hvor W, hvis til stede, er O, N eller S; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; (c) -(CH2)n-W-(CH2)m-Z, hvor n og m hver især uafhængigt er 1 eller 2; hvor W er O, N, S eller sulfonyl; forudsat at hvis W er O, N eller S, så er Z nitro, cyano eller halogen; og forudsat at hvis W er sulfonyl, så er Z H; eller (d) -(CH2)n-Z, hvor n er et helt tal fra 1 -4; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; Y er H; en reaktiv gruppe udvalgt fra et carboxyl, en amin, en ester, en thioester, et sulfonylhalid, en alkohol, en thiol, en succinimidylester, et isothiocyanat, et iodoacetamid, et maleimid og et hydrazin; eller en detekter-bar markering, et lægemiddel, et toksin, et peptid, et polypeptid, en epitop-tag eller et medlem af et specifikt bindingspar; og Ri er udvalgt fra en carboxylsyre, en alkylester, en arylester, en substitueret arylester, et aldehyd, et amid, et arylamid, et alkylhalid, en thioester, en sul-fonylester, en alkylketon, en arylketon, en substitueret arylketon, et halosul-fonyl, en nitril og et nitro.
3. Forbindelse ifølge krav 1, hvor: hvert af X og X' uafhængigt er: (a)H; (b) et eller to halogenatomer (f.eks. bromo, chlor, fluor, iodo); (c) -W-(CH2)n-Z, hvor n er et helt tal fra 1-4; hvor W, hvis til stede, er O, N eller S; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; (d) -(CH2)n-W-(CH2)m-Z, hvor n og m hver især uafhængigt er 1 eller 2; hvor W er O, N, S eller sulfonyl; forudsat at hvis W er O, N eller S, så er Z nitro, cyano eller halogen; og forudsat at hvis W er sulfonyl, så er Z H; eller (e) -(CH2)n-Z, hvor n er et helt tal fra 1 -4; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; Y er et carboxyl, et amin, en thioester, et sulfonylhalid, en alkohol, en thiol, en succinimidylester, et isothiocyanat, et iodoacetamid, et maleimid eller et hydrazin; eller en fluorescerende markering, et lægemiddel, et toksin, et peptid, et polypeptid, et epitop-tag eller et medlem af et specifikt bindingspar; og Ri er udvalgt fra en carboxylsyre, en alkylester, en arylester, en substitueret arylester, et aldehyd, et amid, et arylamid, et alkylhalid, en thioester, en sul-fonylester, en alkylketon, en arylketon, en substitueret arylketon, et halosul-fonyl, en nitril og et nitro.
4. Forbindelse ifølge krav 3, hvor X er to fluoratomer, og X' er H.
5. Forbindelse ifølge krav 3, hvor X og X' begge er H.
6. Forbindelse ifølge et af kravene 1 til 3, hvor X og X' begge er fluor.
7. Forbindelse et af kravene 1 til 6, hvor Y er et fluorphor.
8. Forbindelse ifølge et af kravene 1 til 6, hvor Y er et medlem af et specifikt bindingspar.
9. Forbindelse ifølge et af kravene 1 til 6, hvor Y er biotin.
10. Forbindelse ifølge krav 9, hvor forbindelsen har strukturen:
11. Forbindelse ifølge et af kravene 1 til 6, hvor Y er et epitop-tag.
12. Forbindelse til anvendelse i en fremgangsmåde til diagnosticering eller en fremgangsmåde til terapi, hvor forbindelsen er et modificeret cycloalkyn med formel
j hvor: hvert af X og X' uafhængigt er: (a) H; (b) et eller to halogenatomer (f.eks. bromo, chlor, fluor, iodo); (c) -W-(CH2)n-Z, hvor n er et helt tal fra 1-4; hvor W, hvis til stede, er O, N eller S; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; (d) -(CH2)n-W-(GH2)m-Z, hvor n og m hver især uafhængigt er 1 eller 2; hvor W er O, N, S eller sulfonyl; forudsat at hvis W er O, N eller S, så er Z nitro, cyano eller halogen; og forudsat at hvis W er sulfonyl, så er Z H; eller (e) -(CH2)n-Z, hvor n er et helt tal fra 1 -4; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; Y er en detekterbar markering, et lægemiddel, et toksin, et peptid, et po-lypeptid, et epitop-tag eller et medlem af et specifikt bindingspar; og Ri er udvalgt fra en carboxylsyre, en alkylester, en arylester, en substitueret arylester, et aldehyd, et amid, et arylamid, et alkylhalid, en thioester, en sul- fonylester, en alkylketon, en arylketon, en substitueret arylketon, et halosul-fonyl, en nitril og et nitro.
13. Forbindelse til anvendelse ifølge krav 12, hvor fremgangsmåden omfatter trinnene med at omsætte et azid af et målmolekyle med det modificerede cycloalkyn, og omsætningen frembringer et konjugat mellem azidet af målmolekylet og det modificerede cycloalkyn.
14. Forbindelse til anvendelse ifølge krav 12, hvor fremgangsmåden er til syntetisk modificering af en cellekomponent, hvilken fremgangsmåde omfatter: indføring af en azidenhed i en cellekomponent, hvorved der frembringes en azid-modificeret cellekomponent; og det at bringe cellen, som omfatter den azid-modificerede cellekomponent, i kontakt med en reaktiv partner omfattende det modificerede cycloalkyn, hvor kontakten foregår under fysiologiske betingelser; og kontakten med den reaktive partner resulterer i en omsætning mellem azidgruppen af den azid-modificerede cellekomponent og cycloalkynet af den reaktive partner, hvorved cellekomponenten modificeres syntetisk og kovalent.
15. In wYro-fremgangsmåde til kemoselektiv ligation af et målmolekyle omfattende et azid, hvilken fremgangsmåde omfatter: omsætning af et azid af et målmolekyle med et modificeret cycloalkyn, og omsætningen frembringer et konjugat mellem azidet af målmolekylet og det modificerede cycloalkyn, hvor det modificerede cycloalkyn har formlen
hvor: hvert af X og X' uafhængigt er: (a) Η; (b) et eller to halogenatomer (f.eks. bromo, chlor, fluor, iodo); (c) -W-(CH2)n-Z, hvor n er et helt tal fra 1-4; hvor W, hvis til stede, er O, N eller S; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; (d) -(CH2)n-W-(CH2)m-Z, hvor n og m hver især uafhængigt er 1 eller 2; hvor W er O, N, S eller sulfonyl; forudsat at hvis W er O, N eller S, så er Z nitro, cyano eller halogen; og forudsat at hvis W er sulfonyl, så er Z H; eller (e) -(CH2)n-Z, hvor n er et helt tal fra 1 -4; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; Y er en detekterbar markering, et lægemiddel, et toksin, et peptid, et po-lypeptid, et epitop-tag eller et medlem af et specifikt bindingspar; og Ri er udvalgt fra en carboxylsyre, en alkylester, en arylester, en substitueret arylester, et aldehyd, et amid, et arylamid, et alkylhalid, en thioester, en sul-fonylester, en alkylketon, en arylketon, en substitueret arylketon, et halosul-fonyl, en nitril og et nitro.
16. Fremgangsmåde ifølge et af kravene 13-15, hvorved omsætningen udføres under vandige betingelser.
17. Fremgangsmåde ifølge et af kravene 13-15, hvorved omsætningen udføres under fysiologiske betingelser.
18. Forbindelse til anvendelse ifølge krav 12 eller 13 eller fremgangsmåderne ifølge et af kravene 15 til 17, hvor målmolekylet er et sukker.
19. Forbindelse til anvendelse ifølge krav 12 eller 13 eller fremgangsmåderne ifølge et af kravene 15 til 17, hvor sukkeret er et substrat af sialinsyrebiosyntese.
20. Forbindelse til anvendelse ifølge krav 12 eller 13 eller fremgangsmåderne ifølge et af kravene 15 til 17, hvor sukkeret er mannosamin eller acetyleret mannosamin.
21. Forbindelse til anvendelse ifølge krav 12 eller 13 eller fremgangsmåderne ifølge et af kravene 15 til 17, hvor målmolekylet er en aminosyre.
22. Forbindelse til anvendelse ifølge krav 12 eller 13 eller fremgangsmåderne ifølge et af kravene 15 til 17, hvor målmolekylet, som omfatter azidet, er ek-sprimeret på en celleoverflade.
23. In v/fro-fremgangsmåde til syntetisk modificering af en cellekomponent, hvilken fremgangsmåde omfatter: indføring af en azidenhed i en cellekomponent, hvorved der frembringes en azid-modificeret cellekomponent; og det at bringe cellen, som omfatter den azid-modificerede cellekomponent, i kontakt med en reaktiv partner omfattende et modificeret cycloalkyn, hvor kontakten foregår under fysiologiske betingelser; og kontakten med den reaktive partner resulterer i en omsætning mellem azidgruppen af den azid-modificerede cellekomponent og cycloalkynet af den reaktive partner, hvorved cellekomponenten modificeres syntetisk og kovalent, hvor det modificerede cycloalkyn har formlen
hvor: hvert af X og X' uafhængigt er: (a) H; (b) et eller to halogenatomer (f.eks. bromo, chlor, fluor, iodo); (c) -W-(CH2)n-Z, hvor n er et helt tal fra 1-4; hvor W, hvis til stede, er O, N eller S; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; (d) -(CH2)n-W-(CH2)m-Z, hvor n og m hver især uafhængigt er 1 eller 2; hvor W er O, N, S eller sulfonyl; forudsat at hvis W er O, N eller S, så er Z nitro, cyano eller halogen; og forudsat at hvis W er sulfonyl, så er Z H; eller (e) -(CH2)n-Z, hvor n er et helt tal fra 1-4; og hvor Z er nitro, cyano, sulfonsyre eller et halogen; Y er en detekterbar markering, et lægemiddel, et toksin, et peptid, et po-lypeptid, et epitop-tag eller et medlem af et specifikt bindingspar; og Ri er udvalgt fra en carboxylsyre, en alkylester, en arylester, en substitueret arylester, et aldehyd, et amid, et arylamid, et alkylhalid, en thioester, en sul-fonylester, en alkylketon, en arylketon, en substitueret arylketon, et halosul-fonyl, en nitril og et nitro.
24. Forbindelse til anvendelse ifølge krav 14 eller fremgangsmåde ifølge krav 23, hvor cellekomponenten er et polypeptid.
25. Forbindelse til anvendelse ifølge krav 14 eller fremgangsmåde ifølge krav 23, hvor R-ι er en alkylester.
26. Forbindelse til anvendelse ifølge krav 14 eller fremgangsmåde ifølge krav 23, hvor alkylesteren er en methylester.
27. Forbindelse til anvendelse ifølge et af kravene 12 til 14 eller fremgangsmåderne ifølge et af kravene 15 til 24, hvor forbindelsen er ifølge et af kravene 1 til 11.
DK05823231.5T 2004-11-01 2005-10-31 Sammensætninger og fremgangsmåder til modificering af biomolekyler DK1812031T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62420204P 2004-11-01 2004-11-01
PCT/US2005/039269 WO2006050262A2 (en) 2004-11-01 2005-10-31 Compositions and methods for modification of biomolecules

Publications (1)

Publication Number Publication Date
DK1812031T3 true DK1812031T3 (da) 2015-09-14

Family

ID=36319735

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05823231.5T DK1812031T3 (da) 2004-11-01 2005-10-31 Sammensætninger og fremgangsmåder til modificering af biomolekyler

Country Status (6)

Country Link
US (2) US7807619B2 (da)
EP (1) EP1812031B1 (da)
DK (1) DK1812031T3 (da)
ES (1) ES2545533T3 (da)
PT (1) PT1812031E (da)
WO (1) WO2006050262A2 (da)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2545533T3 (es) * 2004-11-01 2015-09-11 The Regents Of The University Of California Composiciones y métodos para modificación de biomoléculas
EP2290369B1 (en) * 2004-12-22 2013-08-14 California Institute Of Technology Methods for proteomic profiling using non-natural amino acids
WO2007047668A2 (en) * 2005-10-14 2007-04-26 California Institute Of Technology Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells
CA2663580C (en) 2006-09-18 2015-03-17 Compugen Ltd Bioactive peptides and method of using same
US8244021B2 (en) * 2006-12-20 2012-08-14 Ventana Medical Systems, Inc. Quantitative, multispectral image analysis of tissue specimens stained with quantum dots
JP5355561B2 (ja) 2007-07-12 2013-11-27 コンピュゲン エルティーディー． 生物活性ペプチドおよびその使用方法
CA2698369C (en) 2007-09-04 2018-01-23 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US8703904B2 (en) * 2007-09-19 2014-04-22 The Regents Of The University Of Colorado Hydrogels and methods for producing and using the same
US8034396B2 (en) * 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
EP2297344B1 (en) 2008-05-16 2018-03-14 Life Technologies Corporation Dual labeling methods for measuring cellular proliferation
FR2935836B1 (fr) 2008-09-08 2012-11-23 Commissariat Energie Atomique Nanocristaux semi-conducteurs
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AU2010215202A1 (en) 2009-02-21 2011-10-13 Covidien Lp Crosslinked fibers and method of making same using UV radiation
WO2010096649A1 (en) 2009-02-21 2010-08-26 Tyco Healthcare Group Lp Medical devices having activated surfaces
US9273191B2 (en) 2009-02-21 2016-03-01 Sofradim Production Medical devices with an activated coating
EP2398941B1 (en) 2009-02-21 2016-07-13 Sofradim Production Crosslinked fibers and method of making same by extrusion
EP2398524B1 (en) 2009-02-21 2017-07-12 Covidien LP Medical devices having activated surfaces
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
CA2753165A1 (en) 2009-02-21 2010-08-26 Sofradim Production Compounds and medical devices activated with solvophobic linkers
US8968733B2 (en) 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
US8956603B2 (en) 2009-02-21 2015-02-17 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
AU2010215194A1 (en) 2009-02-21 2011-10-13 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
AU2010215200A1 (en) 2009-02-21 2011-10-13 Sofradim Production Apparatus and method of reaching polymers by exposure to UV radiation to produce injectable medical devices
US8877170B2 (en) 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
US8663689B2 (en) * 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
FR2943344B1 (fr) 2009-03-18 2011-04-15 Commissariat Energie Atomique Nouveaux composes silanes porteurs d'une chaine carbonee cyclique comprenant une fonction alcyne pour fonctionnaliser des supports solides et immobiliser sur ces supports des molecules biologiques
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
US8519122B2 (en) 2010-02-12 2013-08-27 The Regents Of The University Of California Compositions and methods for modification of biomolecules
AU2011232356B2 (en) 2010-03-25 2015-02-05 Covidien Lp Functionalized adhesive for medical devices
US8795331B2 (en) 2010-03-25 2014-08-05 Covidien Lp Medical devices incorporating functional adhesives
WO2011117745A2 (en) 2010-03-25 2011-09-29 Sofradim Production Surgical fasteners and methods for sealing wounds
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
JP6034283B2 (ja) 2010-03-26 2016-11-30 トラスティーズ・オブ・ダートマス・カレッジ Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
FR2959061B1 (fr) 2010-04-20 2012-05-11 Commissariat Energie Atomique Substrat fonctionnalise et ses applications
CA2804263A1 (en) 2010-06-29 2012-01-12 Tyco Healthcare Group Lp Microwave-powered reactor and method for in situ forming implants
AU2011272941B2 (en) 2010-06-30 2014-05-29 Compugen Ltd. C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
WO2016030888A1 (en) 2014-08-26 2016-03-03 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
CA2805987C (en) 2010-07-27 2019-04-09 Sofradim Production Polymeric fibers having tissue reactive members
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
WO2012054749A1 (en) 2010-10-20 2012-04-26 Li-Cor, Inc. Cyanine dyes and their conjugates
US20140056811A1 (en) 2010-12-27 2014-02-27 Compugen Ltd. New cell-penetrating peptides and uses thereof
SG194099A1 (en) 2011-04-15 2013-11-29 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012166560A1 (en) 2011-05-27 2012-12-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
JP2015512616A (ja) 2012-02-01 2015-04-30 コンピュゲン エルティーディー． Ｃ１ｏｒｆ３２抗体およびがんの治療のためのその使用
EP2858676B1 (en) 2012-06-07 2019-03-13 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
CA2876706A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
NZ724593A (en) 2012-06-19 2019-05-31 Ambrx Inc Anti-cd70 antibody drug conjugates
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
CN105246507B (zh) 2012-09-07 2019-01-25 达特茅斯大学理事会 用于诊断和治疗癌症的vista调节剂
US9732367B2 (en) 2012-09-24 2017-08-15 Medimmune Limited Cell lines
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
DK2991683T3 (da) 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
EP3010548A1 (en) 2013-06-21 2016-04-27 Innate Pharma Enzymatic conjugation of polypeptides
EP2818867A1 (en) 2013-06-27 2014-12-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies conjugated to at least one nucleic acid molecule and their use in multiplex immuno-detection assays
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CA3190821A1 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
JP6479022B2 (ja) 2014-01-14 2019-03-06 ヨーロピアン モレキュラー バイオロジー ラボラトリーＥｕｒｏｐｅａｎ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ Ｌａｂｏｒａｔｏｒｙ 分子標識のための複数の環化付加反応
US9410958B2 (en) 2014-03-25 2016-08-09 The Regents Of The University Of California Alkyne-activated fluorogenic azide compounds and methods of use thereof
US10550190B2 (en) * 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
WO2015187651A1 (en) 2014-06-02 2015-12-10 Li-Cor, Inc. Therapeutic and diagnostic probes
CN106794362B (zh) 2014-06-09 2021-07-06 乔治亚州立大学研究基金会股份有限公司 用于治疗应用的一氧化碳-释放分子及其制备和使用方法
EP3154585B1 (en) 2014-06-11 2022-02-23 Kathy A. Green Use of vista agonists and antagonists to suppress or enhance humoral immunity
EP2974744A1 (en) 2014-07-16 2016-01-20 Stichting Katholieke Universiteit Strain-promoted oxidation controlled cycloaddition with high reaction rate
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
WO2016081670A2 (en) 2014-11-21 2016-05-26 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
DE102015203116B4 (de) * 2015-02-20 2018-04-05 Universität Leipzig Symmetrische Cycloalkine
WO2016205545A1 (en) * 2015-06-17 2016-12-22 The Regents Of The University Of California Chemoselective modification of a carrier protein with a strained alkyne-labeled cargo agent
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
EP3322733B1 (en) 2015-07-13 2021-09-15 Compugen Ltd. Hide1 compositions and methods
WO2017027337A1 (en) * 2015-08-13 2017-02-16 The Regents Of The University Of California Bioorthogonal reaction of an amine n-oxide and a boron agent
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
US11786603B2 (en) 2016-02-26 2023-10-17 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
UA125382C2 (uk) 2016-04-15 2022-03-02 Імьюнекст Інк. Антитіла проти людського vista та їх застосування
US11058775B2 (en) 2016-04-26 2021-07-13 Merck Sharp & Dohme Corp. Insulin dimer-incretin conjugates
WO2017191817A1 (ja) 2016-05-02 2017-11-09 味の素株式会社 アジド基含有Ｆｃタンパク質
KR20190003722A (ko) * 2016-05-02 2019-01-09 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 분자 영상화를 위한 이량체화 전략 및 화합물 및/또는 방사선 면역요법
EP3922260A3 (en) 2016-05-24 2022-06-15 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and glp-1 analogues
CA3022623A1 (en) * 2016-05-26 2017-11-30 Berkeley Lights, Inc. Covalently modified surfaces, kits, and methods of preparation and use
CA3032146A1 (en) 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
KR102413013B1 (ko) 2016-12-27 2022-06-23 에프. 호프만-라 로슈 아게 신규한 비오틴-특이적 단일클론 항체 및 그 용도
JP6982075B2 (ja) 2016-12-27 2021-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規のビオチン特異的モノクローナル抗体およびその使用
KR102581439B1 (ko) 2017-01-05 2023-09-21 카 메디컬 리미티드 Sirp알파-41bbl 융합 단백질 및 이의 이용 방법
JP2020505009A (ja) 2017-01-05 2020-02-20 カール メディカル リミテッド Ｐｄ１−４１ｂｂｌ融合タンパク質およびその使用方法
CN107118180A (zh) * 2017-03-08 2017-09-01 苏州金点生物科技有限公司 一种含氮八元环炔衍生物及其制备方法
EP3668518A1 (en) 2017-08-18 2020-06-24 Li-Cor, Inc. Sonodynamic therapy
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
CN111868082A (zh) 2018-02-02 2020-10-30 博奥泰克尼公司 调节vista和vsig3的相互作用的化合物及其制备和使用方法
EP3768780A1 (en) 2018-03-21 2021-01-27 Ecole Polytechnique Federale De Lausanne (Epfl) Azacyanine dyes and use thereof
SG11202009670RA (en) 2018-03-29 2020-10-29 Ambrx Inc Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
MX2021000263A (es) 2018-07-11 2021-05-12 Kahr Medical Ltd Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
CA3108289A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2021532831A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20210317213A1 (en) 2018-08-28 2021-10-14 Ambrx, Inc. Anti-CD3 Antibody Folate Bioconjugates and Their Uses
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
KR20210136014A (ko) 2019-02-12 2021-11-16 암브룩스, 인코포레이티드 항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
SG11202102801TA (en) 2019-04-29 2021-04-29 Illumina Inc Identification and analysis of microbial samples by rapid incubation and nucleic acid enrichment
KR102133823B1 (ko) * 2019-06-12 2020-07-15 한국원자력연구원 퀴논 화합물을 이용한 방사성 원소의 표지방법, 방사성 표지화합물 및 이를 포함하는 방사성 원소 표지 키트
JP2022541742A (ja) 2019-07-11 2022-09-27 カール メディカル リミテッド ヘテロダイマーおよびその使用方法
IL294321A (en) 2020-01-09 2022-08-01 Mersana Therapeutics Inc Antibody-drug conjugates are attached at a specific site with linkers that include peptides
CA3160557A1 (en) 2020-01-31 2021-08-05 Innate Pharma Treatment of cancer
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
CR20220530A (es) 2020-04-22 2022-12-15 Merck Sharp & Dohme Llc CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 ß¿c Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO.
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
WO2022051665A1 (en) * 2020-09-03 2022-03-10 Dyne Therapeutics, Inc. Methods of preparing protein-oligonucleotide complexes
EP4240421A1 (en) * 2020-11-09 2023-09-13 The General Hospital Corporation Bifunctional compounds and methods of using the same
IL302818A (en) 2020-11-25 2023-07-01 Innate Pharma Cancer treatment
KR20240004342A (ko) 2021-04-03 2024-01-11 암브룩스, 인코포레이티드 항-her2 항체-약물 접합체 및 이의 용도
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
EP4201430A1 (en) 2021-12-23 2023-06-28 F. Hoffmann-La Roche AG Modified antibody for site-specific conjugation and its diagnostic use
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2023227660A1 (en) 2022-05-25 2023-11-30 Innate Pharma Nectin-4 binding agents
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077954A (en) * 1996-08-01 2000-06-20 Isis Pharmaceuticals, Inc. Substituted heterocyclic compounds
US20030170917A1 (en) * 2002-03-01 2003-09-11 Roche Diagnostics Corporation Compounds, antibodies, reagent kits, methods of producing antibodies, and methods of detecting analytes
US8431558B2 (en) * 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
ES2545533T3 (es) * 2004-11-01 2015-09-11 The Regents Of The University Of California Composiciones y métodos para modificación de biomoléculas

Also Published As

Publication number Publication date
US7807619B2 (en) 2010-10-05
US20060110782A1 (en) 2006-05-25
US8461298B2 (en) 2013-06-11
EP1812031B1 (en) 2015-06-24
PT1812031E (pt) 2015-10-01
WO2006050262A3 (en) 2006-08-10
ES2545533T3 (es) 2015-09-11
EP1812031A4 (en) 2010-11-24
WO2006050262A2 (en) 2006-05-11
US20110213123A1 (en) 2011-09-01
EP1812031A2 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
DK1812031T3 (da) Sammensætninger og fremgangsmåder til modificering af biomolekyler
US11278554B2 (en) Compositions and methods for modification of biomolecules
US8703936B2 (en) Compositions and methods for modification of biomolecules
Debets et al. Azide: a unique dipole for metal‐free bioorthogonal ligations
AU9569498A (en) Compounds containing six-membered rings, processes for their preparation, and their use as medicaments
US20190389817A1 (en) Compositions and methods for quadricyclane modification of biomolecules
Karaj et al. Photoaffinity labeling and bioorthogonal ligation: Two critical tools for designing “Fish Hooks” to scout for target proteins
WO2019224339A1 (en) Long wavelength emitting chemiluminescent probes
US7416898B2 (en) Chemiluminescent 1,2-dioxetanes
US10759994B2 (en) Luminogenic transition metal-based pyridyl complex and its use
US10421725B2 (en) Alkoxyamines for the treatment of cancers
Baskin Development of copper-free click chemistry and application to imaging glycans in living systems
US11746113B2 (en) Labelled cannabinergic ligands and related analogs
WHITE et al. The chemiluminescence of amides and monoacyl hydrazides based on firefly dehydroluciferin
KR20090059585A (ko) 플루오레세인 유도체, 이의 제조 방법 및 이를 이용한음이온 검출방법
US3246038A (en) Process for the production of 4-[2', 6', 6'-trimethylcyclohexen-(1')-yl]-2-methylbuten-(3)-al
Madea Click a unclick reakce p-hydroxyfenacyl derivátů
Lu Application of electrospray ionization mass spectrometry to organic chemistry and chemistry of fullerenes
Vostrikov et al. Some aspects of selective ozonolysis of 5-allyl (allenyl)-4, 4-dimethoxy-2, 3, 5-trichlorocyclopent-2-enones and their 3-morpholino derivatives
Mathison Part I. Acyl cyanide coupling reactions and the synthesis of β-tricarbonyl natural products. Part II. Oxidation of heteroatom-containing substrates with hypervalent iodine (V) reagents